Product image of Letrozol Devatis (Letrozole) supplied by GNH India

Letrozol Devatis

Active Ingredient:
Letrozole
Origin:
EU

Letrozol Devatis (Letrozole)

Letrozole, the active ingredient in Letrozol Devatis, is an aromatase inhibitor presented as a tablet for oral use. It treats hormone receptor‑positive breast cancer in postmenopausal women by lowering estrogen levels that can fuel tumor growth.

GNH India supplies Letrozol Devatis as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution. Customers benefit from reliable supply chains, competitive pricing, and responsive technical support throughout the order lifecycle.

Manufacturer / TM Owner

Devatis Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Letrozole acts on the estrogen synthesis pathway and is indicated for several breast cancer treatment settings.

  • Advanced hormone receptor‑positive breast cancer: slows disease progression and may extend survival.
  • Post‑surgical adjuvant breast cancer: reduces risk of cancer recurrence after tumor removal.
  • Metastatic breast cancer in postmenopausal women: helps control tumor growth and improve disease control.

How It Works

  • Letrozole reversibly binds to the aromatase enzyme (CYP19A1) in peripheral tissues, blocking the conversion of androstenedione and testosterone to estrone and estradiol. By reducing circulating estrogen concentrations, it deprives estrogen‑dependent tumor cells of a growth stimulus, thereby inhibiting proliferation of hormone‑sensitive breast cancer cells in postmenopausal patients. The inhibition is dose‑dependent and persists for several days after the last dose, allowing steady suppression of estrogen levels throughout the treatment cycle.

Side Effects

Letrozole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Hot flashes: sudden feeling of warmth and sweating.
  • Joint and muscle pain: aches in joints or muscles.
  • Fatigue: persistent tiredness.
  • Nausea: upset stomach and urge to vomit.

Serious or Rare Side Effects

  • Severe bone loss or osteoporosis: increased fracture risk.
  • Elevated liver enzymes: potential liver injury.
  • Cardiovascular events: blood clots or heart problems.
  • Severe allergic reaction: rash, swelling, breathing difficulty.

Precautions & Warnings

When prescribing Letrozol Devatis, clinicians should consider several safety measures.

  • Monitor bone health: assess calcium, vitamin D, and bone density regularly.
  • Check liver function: perform baseline and periodic liver enzyme tests.
  • Evaluate cardiovascular risk: review history of thromboembolism before initiating therapy.
  • Contraindicated in pregnancy: letrozole is pregnancy category X and must not be used by pregnant women.
  • Counsel on hot flashes: inform patients they may experience temperature‑related symptoms and discuss management strategies.
  • Store at ambient temperature: keep below 25°C in the original packaging, protected from moisture.

Avoid Interactions

Letrozol Devatis can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

  • Estrogen‑containing hormone therapy: reduces letrozole efficacy.
  • Tamoxifen: antagonistic effect on estrogen suppression.
  • Strong CYP2C19 inhibitors (e.g., fluconazole): may increase letrozole plasma levels.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inducers (e.g., rifampin): may lower letrozole concentrations.
  • CYP3A4 inhibitors (e.g., ketoconazole): may raise letrozole levels.
  • Warfarin: letrozole may enhance anticoagulant effect, requiring INR monitoring.

Frequently Asked Questions

Letrozol Devatis contains letrozole, an aromatase inhibitor indicated for the treatment of hormone receptor‑positive breast cancer in postmenopausal women. It is used in advanced, metastatic, and adjuvant settings to reduce estrogen‑driven tumor growth.

Letrozole blocks the aromatase enzyme, preventing the conversion of androgens into estrogen. Lowering circulating estrogen deprives estrogen‑dependent breast cancer cells of a key growth signal, thereby inhibiting tumor proliferation in postmenopausal patients.

The prescribed dose of Letrozol Devatis is determined by the treating physician based on the patient’s clinical condition and treatment protocol. Typically, letrozole is administered once daily, but exact dosing and duration must follow the prescriber’s instructions.

Letrozole is classified as pregnancy category X, meaning it is contraindicated during pregnancy because it can cause fetal harm. It is also not recommended for breastfeeding mothers, as it may be excreted in breast milk and affect the infant.

To order Letrozol Devatis, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Letrozole, anastrozole, and exemestane are the three main aromatase inhibitors. Letrozole is often chosen for its potent estrogen suppression and once‑daily dosing. Anastrozole has a similar efficacy profile, while exemestane is a steroidal inhibitor with a slightly different side‑effect spectrum. Choice depends on patient tolerance, prior therapy and physician preference.

Letrozol Devatis tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Keep the product away from moisture, direct sunlight and excessive heat to maintain stability throughout its shelf life.

Letrozol Devatis is taken orally as a tablet with a glass of water. It can be taken with or without food, but patients should follow the specific instructions provided by their healthcare professional for optimal absorption.

Serious risks include severe bone loss or osteoporosis, elevated liver enzymes indicating possible liver injury, cardiovascular events such as blood clots or heart problems, and severe allergic reactions that may cause rash, swelling or breathing difficulty. Patients should report any of these symptoms promptly to their physician.

Letrozol Devatis should not be used by pregnant or breastfeeding women, premenopausal patients, individuals with severe liver impairment, or anyone with known hypersensitivity to letrozole or any tablet excipients. Contraindications are outlined in the prescribing information and must be reviewed before initiating therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Letrozole

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT